Doxorubicin liposome Intravenous and Venetoclax
Determining the interaction of Doxorubicin liposome Intravenous and Venetoclax and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with venetoclax may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of P-glycoprotein-mediated drug efflux in the intestine, liver, and/or kidney by venetoclax. Data are available for the P-gp substrate digoxin. When a single 0.5 mg dose of digoxin was coadministered with a single 100 mg dose of venetoclax, digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 35% and 9%, respectively. MANAGEMENT: Caution is advised when venetoclax is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range such as digoxin and dabigatran etexilate. Alternatives should be considered whenever possible. The manufacturer recommends that drugs sensitive to P-gp inhibition in the gastrointestinal tract be administered at least 6 hours before venetoclax. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate following the initiation or discontinuation of venetoclax. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.
Professional:GENERALLY AVOID: Coadministration with venetoclax may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of P-glycoprotein-mediated drug efflux in the intestine, liver, and/or kidney by venetoclax. Data are available for the P-gp substrate digoxin. When a single 0.5 mg dose of digoxin was coadministered with a single 100 mg dose of venetoclax, digoxin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 35% and 9%, respectively.
MANAGEMENT: Caution is advised when venetoclax is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range such as digoxin and dabigatran etexilate. Alternatives should be considered whenever possible. The manufacturer recommends that drugs sensitive to P-gp inhibition in the gastrointestinal tract be administered at least 6 hours before venetoclax. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate following the initiation or discontinuation of venetoclax.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.
Generic Name: doxorubicin liposomal
Brand name: Doxil, Lipodox, Lipodox 50
Synonyms: Doxorubicin liposomal, DOXOrubicin (Liposomal)
Generic Name: venetoclax
Brand name: Venclexta, Venclexta Starting Pack
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Doxorubicin liposome Intravenous-Venipuncture CPI
- Doxorubicin liposome Intravenous-Venipuncture PX1
- Doxorubicin liposome Intravenous-Venlafaxine
- Doxorubicin liposome Intravenous-Venlafaxine ER
- Doxorubicin liposome Intravenous-Venlafaxine ER Capsules
- Doxorubicin liposome Intravenous-Venlafaxine Extended-Release Capsules
- Venetoclax-Doxy 100
- Venetoclax-Doxycycline
- Venetoclax-Doxycycline Calcium
- Venetoclax-Doxycycline Capsules (Rosacea)
- Venetoclax-Doxycycline Capsules with Omega-3 and Vitamin E Capsules
- Venetoclax-Doxycycline Delayed Release Capsule